# Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

> **NCT04132505** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **DRUG:** Binimetinib
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04132505
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-22
- **Primary completion:** 2026-03-24
- **Final completion:** 2026-03-24
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04132505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04132505, "Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04132505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*